• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

作者信息

Cunningham David, Okines Alicia F C, Ashley Sue

出版信息

N Engl J Med. 2010 Mar 4;362(9):858-9. doi: 10.1056/NEJMc0911925.

DOI:10.1056/NEJMc0911925
PMID:20200397
Abstract
摘要

相似文献

1
Capecitabine and oxaliplatin for advanced esophagogastric cancer.卡培他滨和奥沙利铂用于晚期食管胃癌
N Engl J Med. 2010 Mar 4;362(9):858-9. doi: 10.1056/NEJMc0911925.
2
Capecitabine and oxaliplatin for advanced esophagogastric cancer.卡培他滨与奥沙利铂用于晚期食管胃癌
N Engl J Med. 2008 Jan 3;358(1):36-46. doi: 10.1056/NEJMoa073149.
3
Can cisplatin and infused 5-fluorouracil be replaced by oxaliplatin and capecitabine in the treatment of advanced oesophagogastric cancer? The REAL 2 trial.在晚期食管胃癌的治疗中，顺铂和静脉输注的5-氟尿嘧啶能否被奥沙利铂和卡培他滨替代？REAL 2试验。
Clin Oncol (R Coll Radiol). 2005 Apr;17(2):79-80. doi: 10.1016/j.clon.2004.12.004.
4
Capecitabine and oxaliplatin for advanced esophagogastric cancer.卡培他滨和奥沙利铂用于治疗晚期食管胃癌。
N Engl J Med. 2008 May 1;358(18):1965; author reply 1965. doi: 10.1056/NEJMc080178.
5
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.表柔比星、奥沙利铂和卡培他滨联合或不联合帕尼单抗治疗既往未经治疗的晚期胃食管交界腺癌患者（REAL3）：一项随机、开放标签的 3 期临床试验。
Lancet Oncol. 2013 May;14(6):481-9. doi: 10.1016/S1470-2045(13)70096-2. Epub 2013 Apr 15.
6
Validation of the Royal Marsden hospital prognostic index in advanced esophagogastric cancer using individual patient data from the REAL 2 study.利用REAL 2研究的个体患者数据对皇家马斯登医院预后指数在晚期食管胃癌中的有效性进行验证。
J Clin Oncol. 2009 Jul 1;27(19):e3-4. doi: 10.1200/JCO.2009.22.0863. Epub 2009 May 26.
7
Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.蒽环类药物、铂类和氟嘧啶联合化疗治疗晚期食管癌患者的血栓栓塞：英国国家癌症研究所上消化道临床研究组的报告
J Clin Oncol. 2009 Aug 10;27(23):3786-93. doi: 10.1200/JCO.2008.19.4274. Epub 2009 Apr 27.
8
Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.局部晚期食管胃腺癌围手术期铂类化疗：术后化疗对预后有重大影响。
Eur J Surg Oncol. 2015 Oct;41(10):1300-7. doi: 10.1016/j.ejso.2015.07.010. Epub 2015 Jul 29.
9
Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.多西他赛、奥沙利铂和卡培他滨联合方案用于晚期胃癌或胃食管腺癌的可行性研究
Hematol Oncol Stem Cell Ther. 2010;3(2):55-9. doi: 10.1016/s1658-3876(10)50035-9.
10
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.表柔比星、奥沙利铂和卡培他滨联合或不联合帕尼单抗治疗晚期胃食管交界腺癌：前瞻性多中心、随机、II/III 期 REAL-3 试验的剂量探索研究。
J Clin Oncol. 2010 Sep 1;28(25):3945-50. doi: 10.1200/JCO.2010.29.2847. Epub 2010 Aug 2.

引用本文的文献

1
Short- and long-term outcomes after perioperative EOX therapy versus upfront surgery for gastric cancer: a single-centre propensity score-matched cohort study.围手术期EOX治疗与胃癌 upfront 手术的短期和长期结局：一项单中心倾向评分匹配队列研究
BMC Surg. 2025 Apr 28;25(1):184. doi: 10.1186/s12893-025-02919-4.
2
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON-SEOM registry.晚期 HER2 阴性食管胃腺癌的首选铂类和氟嘧啶类方案是什么？来自 AGAMENON-SEOM 登记研究的 1293 例患者的结果。
Clin Transl Oncol. 2024 Jul;26(7):1674-1686. doi: 10.1007/s12094-024-03388-6. Epub 2024 Feb 15.
3
Mutational signature dynamics shaping the evolution of oesophageal adenocarcinoma.
突变特征动态变化塑造食管腺癌的演进。
Nat Commun. 2023 Jul 15;14(1):4239. doi: 10.1038/s41467-023-39957-6.
4
CCL19/CCR7 drives regulatory T cell migration and indicates poor prognosis in gastric cancer.CCL19/CCR7 驱动调节性 T 细胞迁移，并预示胃癌预后不良。
BMC Cancer. 2023 May 19;23(1):464. doi: 10.1186/s12885-023-10882-7.
5
Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study.新辅助程序性死亡蛋白1（PD-1）阻断联合化疗与单纯化疗治疗局部晚期II-III期胃癌的单中心回顾性研究
Transl Oncol. 2023 May;31:101657. doi: 10.1016/j.tranon.2023.101657. Epub 2023 Mar 17.
6
Cancerous inhibitor of protein phosphatase 2A enhances chemoresistance of gastric cancer cells to oxaliplatin.蛋白磷酸酶2A的癌性抑制剂增强胃癌细胞对奥沙利铂的化疗耐药性。
World J Gastrointest Oncol. 2023 Feb 15;15(2):286-302. doi: 10.4251/wjgo.v15.i2.286.
7
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.回顾性比较氟尿嘧啶和顺铂与改良 DCF 方案作为转移性胃腺癌一线化疗的疗效。
Turk J Med Sci. 2022 Oct;52(5):1559-1568. doi: 10.55730/1300-0144.5496. Epub 2022 Oct 19.
8
Optimal First-Line Therapy for Metastatic Adenocarcinoma of the Esophagus.转移性食管腺癌的最佳一线治疗。
Curr Treat Options Oncol. 2022 Dec;23(12):1748-1760. doi: 10.1007/s11864-022-01029-0. Epub 2022 Oct 22.
9
Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer.针对胃癌中Claudin18.2的抗原特异性T细胞免疫疗法
Cancers (Basel). 2022 Jun 2;14(11):2758. doi: 10.3390/cancers14112758.
10
Comparison of the Pathological Response and Adverse Effects of Oxaliplatin and Capecitabine versus Paclitaxel and Carboplatin in the Neoadjuvant Chemoradiotherapy Treatment Approach for Esophageal and Gastroesophageal Junction Cancer: A Randomized Control Trial Study.奥沙利铂和卡培他滨与紫杉醇和卡铂在食管及食管胃交界癌新辅助放化疗治疗方案中的病理反应和不良反应比较：一项随机对照试验研究
Med J Islam Repub Iran. 2021 Oct 25;35:140. doi: 10.47176/mjiri.35.140. eCollection 2021.